Ibogaine is not explicitly scheduled or prohibited under Belizean law, placing it in a legal grey area that allows treatment clinics to operate without direct criminal exposure. Last verified: April 22, 2026.

Current Legal Status

Belize's primary drug control legislation is the Misuse of Drugs Act (Chapter 103 of the Laws of Belize). This Act enumerates controlled substances across several schedules. Ibogaine — and its primary active alkaloid, ibogaine hydrochloride — does not appear in any schedule of the Misuse of Drugs Act. Similarly, the broader plant source, Tabernanthe iboga, is not listed as a controlled plant or precursor substance under Belizean law.

Because ibogaine is neither explicitly legal nor explicitly illegal, its status is best described as unscheduled. This means:

  • Simple possession of ibogaine is not a criminal offense under the Misuse of Drugs Act.
  • There is no formal licensing framework for ibogaine administration or treatment providers.
  • No religious exemption is necessary, as no prohibition exists to require one.
  • Importation of ibogaine may implicate customs and import regulations depending on how the substance is classified at the point of origin and at Belizean customs, though no specific prohibition applies domestically.

Belize is a signatory to the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances (1988) and related treaties. However, ibogaine is not scheduled under the UN Convention on Psychotropic Substances (1971), which means Belize has no treaty obligation to control it. The World Health Organization has repeatedly reviewed ibogaine for international scheduling and, to date, has not recommended placing it under international control.

Note: An unscheduled status does not mean ibogaine is formally approved, regulated, or endorsed by Belizean health authorities. The absence of prohibition is not equivalent to affirmative legal protection for providers or patients.

Treatment Centers

Belize has attracted a small number of ibogaine treatment providers, largely due to its English-speaking population, proximity to the United States, relatively accessible international travel connections, and the legal grey area that permits operations without the compliance burden found in more heavily regulated jurisdictions. Providers operating in Belize typically cater to clients traveling from North America and Europe.

Because there is no formal licensing or accreditation framework specific to ibogaine in Belize, providers vary significantly in their medical standards, screening protocols, and staff qualifications. Prospective patients should conduct thorough due diligence before committing to any facility.

For a full, up-to-date directory of ibogaine clinics operating in Belize, see our ibogaine clinic directory.

How People Access Ibogaine in Belize

The following describes factual access pathways documented in publicly available sources. This is not a recommendation to pursue any particular course of action.

  • Medical tourism: The most common pathway. Individuals — predominantly from the United States, Canada, and the United Kingdom — travel to Belize specifically to receive ibogaine treatment at private clinics. Belize's proximity to the U.S. and direct flight connections from major hubs make this logistically straightforward relative to more distant destinations such as Mexico or Portugal.
  • Private retreat programs: Some providers operate as wellness retreats rather than clinics, offering ibogaine in a ceremonial or therapeutic context outside of formal medical settings.
  • Importation for personal use: Some individuals report importing ibogaine for personal use. This carries risk at the point of departure if the substance is scheduled in the country of origin (e.g., ibogaine is a Schedule I substance in the United States). Belizean customs does not list ibogaine as a prohibited import, but enforcement practices can be inconsistent.
Warning: Traveling internationally with ibogaine from a country where it is scheduled — such as the United States — is a serious federal offense regardless of the legal status at the destination. Do not transport controlled substances across international borders.

Recent Legal Developments

No legislation specifically targeting ibogaine has been introduced in the Belizean National Assembly within the past two years. Belize has not announced any review of its Misuse of Drugs Act schedules that would incorporate ibogaine as of the current date.

Regionally, interest in ibogaine reform has grown in neighboring countries. Mexico has seen expanding legal use and research, and the United States has seen state-level decriminalization efforts in Texas, Colorado, and Utah, as well as FDA Breakthrough Therapy designations for ibogaine in addiction and PTSD research contexts. These developments have increased the visibility of Belize as a medical tourism destination for North Americans, though they have not yet triggered any formal domestic legislative response in Belize.

The Belizean Ministry of Health and Wellness has not issued any formal guidance, advisory, or policy statement specifically addressing ibogaine treatment providers or patients as of April 2026. Providers currently operate without formal government acknowledgment in either direction.

Risks of Seeking Treatment in Belize

While the legal environment in Belize is permissive, prospective patients should carefully consider the following risks:

  • No regulatory oversight: Because ibogaine is unscheduled and there is no specific licensing framework, treatment providers are not subject to government inspection or minimum medical standards specific to ibogaine. This creates wide variability in quality between providers.
  • Cardiac risk: Ibogaine is associated with QT interval prolongation and has been linked to fatalities, predominantly in individuals with pre-existing cardiac conditions or those who combined ibogaine with other substances. In a well-resourced setting, a 12-lead ECG and cardiac screening are standard pre-treatment requirements. Not all Belizean providers enforce equivalent standards.
  • Emergency medical infrastructure: Belize's medical infrastructure, particularly outside of Belize City, is limited compared to major urban centers in the United States, Canada, or Western Europe. In the event of a cardiac emergency during ibogaine administration, response times and specialist availability may be inadequate.
  • No legal recourse: In the absence of a regulatory framework, patients who experience harm have limited avenues for legal recourse against providers. Medical malpractice standards applicable to ibogaine specifically have not been established.
  • Drug interaction screening: Ibogaine carries serious and potentially fatal interaction risks with opioids, serotonergic medications (including SSRIs and SNRIs), stimulants, and several other substance classes. Patients should verify that any prospective provider conducts thorough medication and substance history screening.
  • Provider credentials: Confirm that any medical staff involved in the treatment hold valid licenses and that a physician is present — not merely on call — during the active treatment period.
Safety note: Ibogaine carries genuine cardiac risk. Reputable providers require a full cardiac evaluation, including ECG, before administration. Decline treatment from any provider who does not require this screening.

Frequently Asked Questions

Ibogaine is not listed in any schedule of the Misuse of Drugs Act (Chapter 103), which is Belize's primary drug control law. This makes it unscheduled — meaning possession and use are not criminal offenses under Belizean drug law. However, ibogaine is not formally approved or regulated by Belizean health authorities either. It exists in a legal grey area rather than a clearly defined legal status.
Receiving ibogaine treatment within Belize does not appear to violate Belizean law given the current unscheduled status. However, there are several important considerations: (1) Do not carry ibogaine from another country, as it may be controlled at your point of departure. (2) Entry into Belize is subject to customs inspection. (3) U.S. citizens should be aware that ibogaine remains a Schedule I substance in the United States, and the legal consequences of seeking treatment abroad do not negate domestic law. Consult a licensed attorney before making any travel decisions.
There is no government licensing framework specific to ibogaine treatment in Belize. Clinics may hold general business licenses, and medical staff may hold individual professional licenses, but no regulatory body oversees ibogaine administration specifically. This is a significant distinction from jurisdictions such as Canada, where some ibogaine providers operate under Health Canada exemptions and are subject to oversight.
Safety depends heavily on the individual provider's standards, not on the country's legal framework. Ibogaine carries documented cardiac risks regardless of where it is administered. Key safety indicators include mandatory cardiac screening (ECG and cardiac history), the presence of licensed medical personnel during the full treatment window, thorough drug interaction screening, and access to emergency medical equipment including a defibrillator. Belize's general medical infrastructure is less developed than many Western countries, which may affect emergency response capability. Independently verify any clinic's medical protocols before committing to treatment.
In most cases, receiving ibogaine treatment abroad and returning home without carrying any substance is unlikely to result in prosecution, as enforcement of drug laws typically requires possession of a controlled substance within the jurisdiction. However, this is not guaranteed in all jurisdictions, and laws vary. U.S. federal law, for instance, prohibits conspiracy and aiding the use of Schedule I substances in some circumstances. Do not bring ibogaine or related substances back across any border. This is not legal advice — consult a licensed attorney in your home jurisdiction for guidance specific to your situation.
No publicly available legislative proposals to schedule ibogaine have been introduced in the Belizean National Assembly as of April 2026. Belize has no treaty obligation to schedule ibogaine, as it is not controlled under the UN Convention on Psychotropic Substances. Absent international pressure or a domestic policy shift, a significant change in Belize's legal posture toward ibogaine appears unlikely in the near term — though this can change and should be monitored.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.